Sino Biopharmaceutical to Acquire LaNova Medicines in $951 Million Deal Focused on PD-1xVEGF Cancer Therapies

Sino Biopharmaceutical has announced plans to acquire LaNova Medicines, a Chinese pharmaceutical company, in a deal valued at up to $951 million. LaNova is known for its partnerships with global pharmaceutical giants Merck & Co. and AstraZeneca, particularly in the development of PD-1xVEGF bispecific therapies. The acquisition reflects growing interest in this innovative drug class within China, following significant attention from Western pharmaceutical companies.

LaNova Medicines specializes in developing treatments that combine PD-1 inhibitors with VEGF-targeting mechanisms, an approach aimed at enhancing cancer immunotherapy outcomes. The company’s collaborations with Merck and AstraZeneca have positioned it as a key player in this field. Sino Biopharmaceutical’s decision to purchase LaNova highlights the increasing momentum of PD-1xVEGF research and commercialization efforts within the Chinese market. This acquisition comes amid broader trends of mergers and acquisitions in the biopharmaceutical industry as companies seek to expand their portfolios and strengthen their positions in emerging therapeutic areas.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

Date: July 15, 2025

Related posts:

Hidden Neural Stem Cells May Hold Key to Brain Regeneration Eli Lilly Partners with Camurus in $870 Million Deal to Develop Long-Lasting Obesity Treatments European Council Advances New EU Rules to Simplify Pharmaceutical Regulations Study Finds Link Between Prebiotics and Increased GABA Levels for Potential Neurological Disease Treatment

Author

Mark Chiang